ERBB2 and gastric cancer: Approved for HER2-positive breast and gastric cancers, trastuzumab deruxtecan achieves high cytotoxic potency (IC50 in the low nanomolar range) and induces significant bystander killing, enabling activity even in tumors with moderate or low HER2 expression [115].